Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIAM: Induction Chemo-immunotherapy for Locoregionally Advanced Penile Cancer
NCT06353906Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2024
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of pembrolizumab in penile squamous cell carcinoma (PSCC), sponsored by Netherlands Cancer Institute. Started Aug 2024; status: recruiting.
02
Drugs
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NCT06353906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06353906.